Not exact matches
«These events offer several venues and
platforms to share the exciting progress ViaCyte is making in developing novel
cell replacement therapies for diabetes,» said Paul Laikind, PhD, President and CEO of ViaCyte.
Ultimately, we use all this information to establish innovative culture techniques for generating unlimited neural stem
cell sources for the derivation of specific types of clinically relevant neuronal or glial
cells, for their use in disease modelling and drug discovery
platforms, and towards refining their efficacy for future
cell replacement - based therapy.
The new iPS
cells generated using novel methods may represent biomedically - and clinically - ideal
cells, providing potential
platforms for studying human disease mechanisms and achieving the long - term goal of personalized
cell -
replacement therapy.